ROGER S KERESZTES MD
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy (NCT03904108) | ROGER S KERESZTES MD | 2019-06-27 |
Track ROGER S KERESZTES MD automatically
Every clearance here is in the API, with alerts when new ones post.